knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 01:36:10 - browse：94691

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： 'Investigate these claims': UFO transparency at center of House hearing

leisure time

WSS

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

US soldier in North Korean custody after crossing DMZ line

Senate panel puts off hardest PBM reforms for another day

Device maker Teleflex to acquire urology company for $600M

Wikipedia

knowledge

explore

In age of alternative facts, a scholarly course on calling out crap

'Investigate these claims': UFO transparency at center of House hearing

How one medical school became remarkably diverse

Johnson & Johnson sues to stop Medicare negotiation

Wildfire smoke exposes gaps in outdoor worker protections

The battle over 'scope creep' and who gets to be called 'doctor'

ChatGPT in medicine: STAT answers readers' burning questions

What it's like to live with paralysis for one psychologist

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A look at other Americans who have crossed into North Korea over the years

focus

Why you get paid to donate plasma but not blood

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Johnson & Johnson sues to stop Medicare negotiation

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Biden administration sends mixed signals on US soldier who crossed into North Korea

Rise in cancer among younger people worries and puzzles doctors

hotspot

leisure time

entertainment

hotspot